Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Dec 14, 2015 at 1:50 PM EST

AcelRx Tanks on Pre-NDA Results

AcelRx intends to pursue an ARX-04 indication for moderate-to-severe pain in a medically supervised setting. However, this might be farther…

Jon C. Ogg | Dec 14, 2015 at 1:15 PM EST

Quidel Seen as Good Bet on Flu Season Drugs

Quidel is considered a bet on flu season. The analyst team over at Canaccord Genuity likes Quidel quite a bit.

Chris Lange | Dec 14, 2015 at 9:25 AM EST

What Atara Bio Has Under the Hood After Kidney Drug Failure

Atara Biotherapeutics announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy…

Chris Lange | Dec 14, 2015 at 8:50 AM EST

Could This New Deal Double Akebia Therapeutics?

Akebia Therapeutics led the bulls early on Monday following news of what looks like a big commercialization partnership in Asia.

Chris Lange | Dec 12, 2015 at 10:25 AM EST

5 Key BioPharma Movers That Cannot Be Ignored

Bluebird Bio, Idera Pharmaceuticals and others stood out from other biotech stock with incredible gains or losses over the course…

Chris Lange | Dec 10, 2015 at 11:15 AM EST

Cara Therapeutics Posts Strong Phase 2 Results

Cara Therapeutics saw its stock rise in Wednesday’s session on statistically significant Phase 2 results, but the delight of investors…

Chris Lange | Dec 10, 2015 at 8:50 AM EST

Short Interest in Major Pharma Takes a Giant Leap

The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Chris Lange | Dec 10, 2015 at 8:40 AM EST

Mixed Views on Major Biotech Short Interest

The November 30 short interest data have been compared with the previous report, and short interest was mixed in these…

Chris Lange | Dec 9, 2015 at 1:35 PM EST

Baxalta Rises on FDA Approval

Baxalta was rising in Wednesday’s trading session on news of a key U.S. Food and Drug Administration (FDA) approval.

Chris Lange | Dec 9, 2015 at 11:40 AM EST

Aeterna Zentaris Prices Secondary Offering

Aeterna Zentaris has amended is filing with the U.S. Securities and Exchange Commission (SEC) for its secondary offering.

Chris Lange | Dec 8, 2015 at 11:05 AM EST

Why TherapeuticsMD Is Skyrocketing

TherapeuticsMDwas leading the health care sector in Tuesday’s session on positive top-line results from one of its late-stage trials.

Chris Lange | Dec 8, 2015 at 10:10 AM EST

Why Onconova Is Soaring

Onconova Therapeutics led the bulls early in Tuesday’s trading session on positive data from an ongoing Phase 1/2 clinical trial.

Chris Lange | Dec 7, 2015 at 4:09 PM EST

Jefferies Top Pharma Stock Picks for 2016

Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.

Chris Lange | Dec 7, 2015 at 1:25 PM EST

Why Key Analyst Still Sees Some Upside in Bluebird Bio

Bluebird Bio absolutely tanked in Monday's trading session, based on preclinical and manufacturing data from the American Society of Hematology…

Chris Lange | Dec 7, 2015 at 12:15 PM EST

Why Threshold Pharma Is Imploding

Threshold Pharmaceuticals watched its stock completely collapse in Monday’s session after a joint late-stage study failed to yield positive results.

1 … 231 232 233 234 235 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

AcelRx Tanks on Pre-NDA Results

Quidel Seen as Good Bet on Flu Season Drugs

What Atara Bio Has Under the Hood After Kidney Drug Failure

Could This New Deal Double Akebia Therapeutics?

5 Key BioPharma Movers That Cannot Be Ignored

Cara Therapeutics Posts Strong Phase 2 Results

Short Interest in Major Pharma Takes a Giant Leap

Mixed Views on Major Biotech Short Interest

Baxalta Rises on FDA Approval

Aeterna Zentaris Prices Secondary Offering

Why TherapeuticsMD Is Skyrocketing

Why Onconova Is Soaring

Jefferies Top Pharma Stock Picks for 2016

Why Key Analyst Still Sees Some Upside in Bluebird Bio

Why Threshold Pharma Is Imploding

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Alphabet, Intel, Micron Lead Nasdaq Higher as Oil Drops on Paused Mideast Tensions

State Street Defense Call Perfectly Tees up Trio Of ETFs For An Incredible 2026

PayPal Tumbles 10% Despite Q1 Earnings Beat: Is the Venmo Spin-off Enough to Save the Stock?

Is College Still Worth It? Ron Lieber's Advice for Parents Navigating Shifting Job Market

Caleb Hammer Confronts Husband Hiding an AI Girlfriend From His Wife

Alphabet, Intel, Micron Lead Nasdaq Higher as Oil Drops on Paused Mideast Tensions

State Street Defense Call Perfectly Tees up Trio Of ETFs For An Incredible 2026

Health and Healthcare Articles

All Health and Healthcare Articles

AcelRx Tanks on Pre-NDA Results

Quidel Seen as Good Bet on Flu Season Drugs

What Atara Bio Has Under the Hood After Kidney Drug Failure

Could This New Deal Double Akebia Therapeutics?

5 Key BioPharma Movers That Cannot Be Ignored

Cara Therapeutics Posts Strong Phase 2 Results

Short Interest in Major Pharma Takes a Giant Leap

Mixed Views on Major Biotech Short Interest

Baxalta Rises on FDA Approval

Aeterna Zentaris Prices Secondary Offering

Why TherapeuticsMD Is Skyrocketing

Why Onconova Is Soaring

Jefferies Top Pharma Stock Picks for 2016

Why Key Analyst Still Sees Some Upside in Bluebird Bio

Why Threshold Pharma Is Imploding

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Alphabet, Intel, Micron Lead Nasdaq Higher as Oil Drops on Paused Mideast Tensions

State Street Defense Call Perfectly Tees up Trio Of ETFs For An Incredible 2026

PayPal Tumbles 10% Despite Q1 Earnings Beat: Is the Venmo Spin-off Enough to Save the Stock?

Featured Reads

Is College Still Worth It? Ron Lieber's Advice for Parents Navigating Shifting Job Market

Caleb Hammer Confronts Husband Hiding an AI Girlfriend From His Wife